VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office
LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells.
VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.
LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells. This novel mechanism of action provides advantages relative to safety and efficiency with respect to the vectors currently in use.
When its development phase ends, the advantages of LENTISOMA will position it as one of the vectors of choice for the gene therapies that require it.
Therefore, it is very important that LENTISOMA is correctly protected from the Intellectual Property point of view in the United States, bearing in mind that it is the most powerful country in the development of gene therapies.
This concession is consistent with the growing number of manufacturing projects that VIVEbiotech is developing in the US market (6 projects currently).
Related news
CIC biomaGUNE launches a company that will transform disease diagnosis by using nanosensors
Taldeki Biosolutions will be developing sensors for rapid, cost-effective, robust antibody detection, thus overcoming the stability and cost problems of current in vitro diagnostics
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
CIC nanoGUNE launches a new call: Industry Collaborative Research Positions
Programa honen helburua da ikertzaile profesionalak tokiko erakundeetan sar daitezen erraztea
Companies with greater gender equality perform better in terms of innovation and are more competitive
The study of the SPRI initiative "Women in Industry" shows that gender equality has an impact on the improvement of company results.
SPRI presents the results of the study on the impact of women on industrial competitiveness at the World Manufacturing Forum
The reports is the continuation of the work carried out by the SPRI Group and the Foreign Network office in Milan since 2020 as leader of the Women in Manufacturing expert group.
Europako fabrikazio-ikerketaren etorkizuna
Donostian, egunotan, MANUFUTURE Conference 2023 egiten ari da, hau da, fabrikazio-industriaren etorkizunari buruzko Europako konferentzia.
REBEL TICKETS resale platform, now available on your cell phone
Now you will be able to buy and sell your tickets in a simpler, more comfortable and accessible way.
Basque Open Industry will show Europe its industrial and technological ecosystem at the European SME Week (SME Week) from 13 to 17 November.
Talent, internationalisation, energy-environmental and technology-digital transitions. SME Week 2023. Exhibition and stands at the BEC: “Rebuild Ukraine”.
Aker Solutions selects TUBACEX as a delivery partner for umbilical tubes for key projects on the Norwegian Continental Shelf
An order intake for a sum of more than €70 million is one of the most significant deals in the umbilicals market. Solidifying TUBACEX’s technological position as a supplier of advanced industrial solutions for energy and mobility sectors.
Get to know the assets of the BDIH: 5-axis multi-process milling cell, capable of very high speed operations
The University of the Basque Country offers Basque companies, via the BDIH, the possibility to have at their disposal a 5-axis multi-process milling cell, capable of very high-speed operations.